11th Annual HealthTech Investment Forum

Caresyntax makes surgery safer, smarter and more profitable by converging medical-grade devices, AI-powered technology and clinical services. Founded in 2013, the company delivers a vendor-neutral platform solution which drives efficiencies throughout the peri-and intraoperative environment. For the first time, health care providers can access insights relating to clinical, financial, and operational outcomes from data collected in the operating room. Caresyntax is installed in 3,500 operating rooms across EMEA and US markets and supports over 3 million annual surgeries.

At Q3 Medical Group, our vision of "Creating Value by Helping People" is the heartbeat of our mission. As a pioneering medical device company, we're transforming healthcare with our state-of-the-art innovations in biodegradable and micro-invasive technologies. Specializing in surgical, gastrointestinal, and interventional treatments for both benign and malignant conditions of the Gastrointestinal and Vascular Systems, our groundbreaking innovations are crafted to elevate patient quality of life. By minimizing complications and eliminating the need for follow-up removal procedures, we’re not just improving patient outcomes—we’re also driving down costs and championing sustainability in the healthcare industry. Q3 is a growth stage medical device implant company dedicated to developing groundbreaking, innovative products and bringing them to the global market.

Skymab Biotherapeutics, a French biotech company spun out from the CEA (Commissariat à l'Énergie Atomique) in 2019, focuses on developing anti-GPCR Antibody Drug Conjugates (ADCs) to address critical unmet needs in oncology. Leveraging its proprietary target discovery algorithm and linker platform, Skymab's most advanced ADC candidate, now ready for IND-enabling studies, has been thoroughly validated in multiple animal proof-of-concept studies. This candidate presents significant opportunities for accelerated development in high unmet need indications, given its broad pan-tumor potential.

4D Lifetec offers an Artificial Intelligence (AI) backed immunological liquid biopsy platform that can be scaled offering multiple applications from Screening to Verification to Monitoring. At 4D Lifetec, we recognize the boundless potential of AI in revolutionizing the early detection of cancer. With the power of AI, we are redefining the landscape of cancer diagnostics by opening up the horizon of our breakthrough innovation “4D Lifetest”, the first and only Immunological Liquid Biopsy Platform. Human Peripheral Blood Mononuclear Cells (PBMCs), a group of white blood cells, react immediately as part of the immunological system to the presence of a cancerous tumor: its DNA fragmentation changes its behavior. Our groundbreaking early cancer detection platform hinges on the combination of a proprietary high-precision method combined with the power of our own AI-based analysis tools. It allows us to detect multiple cancers independent from their stage. A biomarker has no clinical use as long as the sensitivity is not above 75 - 80%. 4D Lifetest outperforms the most advanced genomic liquid biopsies regarding sensitivity for cancer stages I and II. However, until now, 4D Lifetest Dx is not yet cancer type specific. Thanks to our investment and further development in our AI applications, this will change within close future. AI combined with 4D Lifetest offers a unique scalability potential not only in volume but also types of applications addressing huge and fast growing market potentials. Our own AI enables 4D Lifetec to define cancer type and subtype detection which is key once the screening is applied. 4D Lifetec owns CE-IVD cerfiticates for its verification assays for breast, lung, prostate and bowel cancer and intents to commercialise its lung verification assay in the US beginning 2026 followed by an IPO at the US stock exchange.

Brightmind.AI is a pioneering neurotechnology company focused on improving brain health through personalized brain stimulation. Leveraging brain monitoring and transcranial magnetic stimulation, the company is developing effective, at-home treatments for neurological conditions such as migraines and dementia. Mission: To revolutionize brain health by making cutting-edge, non-invasive brain stimulation technology accessible for home use, thereby addressing critical challenges in neurological care. First application: Migraine Our first product addresses the literal pain point: migraine. Research indicates that our stimulation protocol reduces migraine attacks by over 6 days a month (placebo effect subtracted) offering a 3x improvement over current treatment options. This has been validated from both independent studies and Brightmind.AI's pilot study. Technology: Brightmind.AI uses a closed-loop system combining transcranial magnetic stimulation with advanced brain monitoring to synchronize and personalize brain stimulation. Partnerships and Funding: The company is backed by Xista, with additional support from FFG and AWS and has raised 3.3M in capital. Awards: Brightmind.AI has received recognition and awards including the rising star award in the European start-up scene in MedTech from Sifted and the Innovator of the Year award in Austria. Vision: To integrate Brightmind.AI’s neurotech solutions into homes worldwide, improving quality of life and mental health on a global scale.

Hy2Care revolutionizes cartilage repair with CartRevive® hydrogel implant of joint-matching composition, enabling the body to heal itself. It was founded by a patient, now in the clinical stage, ready to disrupt orthopedics. Hy2Care® is a ‘spin-off company’ of the Tech Med Centre at the University of Twente (NL) and was founded in 2014. Of the original founders, Prof. Dr. Marcel Karperien and Dr. Sanne Both, continue to be active in the company. Hy2Care’s launching product, the CartRevive® hydrogel implant for cartilage repair in the knee, is in the last phase of a clinical investigation in the Netherlands for European market approval. The first clinical results show significantly superior results compared to existing standard-of-care therapies. With the FDA Breakthrough Design Designation received, Hy2Care is currently preparing for IDE submission and intends to start initialization of its US trial in 2025. Hy2Care’s innovative platform centers on the CartRevive™ hydrogel implant's in-situ formation. Upon application to a cartilage defect, two naturally derived polymers, Dextran and Hyaluronic acid-conjugates, gelate within a minute. Simultaneously, the implant attaches itself to the surrounding cartilage and bone, providing a strongly fixated resorbable scaffold that degrades over time. The joint-mimicking composition forms a natural environment for the patient's cells to quickly populate the implant and initiate the natural repair of the cartilage. The unique therapy provides natural tissue healing, comparable to best-in-class cell-technology, at a fraction of the cost. Hy2Care is currently raising €9M series B round to complete preparations for the US trial, obtain CE mark and initiate first commercial treatments in Europe.

inHEART advances precision medicine in cardiology with AI-based solutions for personalized treatment, prevention, and screening for cardiac diseases.

Lifespin is transforming diagnostics by combining advanced metabolomics, NMR technology, and AI to deliver fast, scalable, and cost-effective health assessments. From a single blood sample, Lifespin generates a digital metabolomic twin, analyzing 250+ biomarkers to detect early signs of non-communicable diseases (NCDs)—including diabetes, cardiovascular risks, and liver dysfunction—before symptoms emerge. With a proprietary database of over 250,000 profiles and validation from 50+ clinical partners, Lifespin’s cloud-based SaaS platform reduces diagnostic costs by up to 10x and supports both clinical and at-home applications. Strategic alliances—such as with IHH Healthcare—accelerate global adoption. Targeting a $100B+ market, Lifespin is leading the shift from reactive care to proactive, data-driven medicine—empowering earlier intervention and better outcomes in the fight against NCDs.

LuSeed Vascular is a pioneering medical technology startup that focuses on advancing neurovascular innovation for treating aneurysms in the brain. Our primary commitment is to create and introduce groundbreaking devices that bring about significant improvements in the treatment outcomes of brain aneurysms. The company’s flagship product, LuSeed’s DOME™, is a minimally invasive, is first of its class “one-and-done” device with the unique ability to treat both Bifurcation and Sidewall Brain aneurysms simply and safely, saving thousands of lives each year and disrupting the global market, valued more than 2.4B$. The company’s leadership features extensive experience in the medical device domain and supported by top global KOLs in its field. LuSeed has commenced its clinical phase, with so far highly promising results.

PamGene is a biomarker services company that has recently developed the IOpener® test. This is a CE-IVD certified product for the prediction of immunotherapy response for cancer patients in several indications (lung, skin, bladder, ovarium, prostate). The blood test is in the pivotal phase of commercialisation in Europe allowing for patient selection and guidance of immune therapy combination strategies in cancer care.

ALVIV is a bio-convergence medical device company developing a disruptive, short, pain-free laser-based treatment for Fecal Incontinence (FI). A condition that affects tens of millions of people around the world (1 of every 12 adults in the US). Currently, with no effective and consistent solutions especially for mild to moderate cases, holding immediate implications on patients' well-being and quality of life. Harnessing tissue regeneration processes, ALVIV’s solution aims to introduce an innovative approach that serves as a breakthrough in FI management; by strengthening the internal sphincter in FI patients, we are addressing the source of the medical problem and not only the symptoms. Our Vision: We strive to become a leading player in FI illness management, with our laser-based treatment and patients standardized AI-based analysis. Scaling up, we will develop a home-use therapy for patients in-order-to provide access to a safe, effective, and easy-to-apply self-treatment option. ALVIV’s team consists of leading experts bringing decades of experience and proven execution capabilities, developing energy-based medical solutions for various indications (from OBGYN, and proctology to autologous fat injection applications), validating them clinically and commercializing in global markets. We are moving fast. With a fully functioning prototype and software, we are already in first-in-human safety and feasibility clinical study stage (Meir Medical Center, Israel). Estimating to finalize patient recruitment within two months.

Gurmit Sandhu Consulting GmbH has been registered with the Basel City commercial register since 2012. With 35 years of experience, its founder and Managing Director, Gurmit Sandhu, is an experienced and respected specialist in the pharmaceuticals industry and digital health. Value Assessment of Digital Health Technologies for improving their market access, reimbursability, and adoption has been a focus since 2019.

Founded in June 2022, Oncosema is a French IVD upstart dedicated to developing, manufacturing and commercializing innovative tests for the detection and quantification of Circulating Tumor Cells in blood as a biomarker of cancer progression.

Panda Surgical, a University College London spinout, is developing the first-ever handheld robotics platform for minimally invasive neurosurgery, offering surgeons enhanced dexterity and decision-support to make these operations safer, more effective, and more widely adopted.

Rosetta Omics is a French healthcare deeptech startup in a mission is to revolutionize precision medicine, starting with cancer, by integrating multiomics data from patient tumors, clinical records, and advanced machine learning/AI algorithms. Our innovative approach aims to enhance the prediction of treatment responses, providing physicians with critical insights to prescribe the most effective therapies for their patients at the right time to save lives and cost. At the moment, response rate at first line is very low and physicians need tools like ours to help them. Additionally, we are collaborating with pharmaceutical companies to discover new biomarkers and targets, aiding in drug discovery and patient stratification during clinical trials to accelerate the development of safe and effective cancer treatments. We have already initiated discussions with several leading pharmaceutical firms.

Swiift Imaging - Quality ultrasound, anytime, anywhere. Ultrasound is the second most used imaging modality (5x more than CT scan) and the only one not to be used in routine tele-imaging. Faced with the significant difficulties in patient access to ultrasound, particularly outside metropolitan areas, Swiift Imaging offers the first long-distance remote robotic ultrasound solution with force feedback allowing the radiologist to apply their know-how as at the patient's bedside. To this end, the company has invested in a strong R&D program, thus ensuring a solid IP. Swiift Imaging's solution is the missing link in the pooling of medical imaging resources. Swiift Imaging offers a remote robotic ultrasound solution made of two interdependent medical devices: - One side for radiologists including ultrasound data transfer and a haptic arm enabling the exam as at the patient's bedside - One for institutions requiring ultrasound scans for their patients with a robotic arm holding the ultrasound probe.

VUS Diagnostics is a genetic focused precision diagnostic company on a mission to help bring personalised treatment approaches to patients. We do this by designing CRISPR based functional assays that address the mechanism underlying the disease biology or drug response. Using such functional assays, we help drug developers identify the patients for whom their precision medicine can reverse disease pathology, or provide more specific cancer treatments.

Brenus Pharma is a French clinical-stage biotech company developing an off-the-shelf platform advancing novel modalities in immuno-oncology. This cutting-edge precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response against evolving tumor cells. www.brenus-pharma.com 

NovaPump's "PERKAT" plaform (from Jena/ Germany) is the novel percutaneous, self-expanding heart-pump for safe implantations and pulsatile circulation support for acute care patients with clear USP’s (mentioned and cited in leading medical text books and papers, award winning: 1st place at German Medical Award, 1st place at Lothar Spaeth Award from EU Commissioner Guenther Oettinger). So- we are currently rasing our serious round B. Comment: We are former inventors & co-founders of the JenaValve technique, too (the worldwide first technique for selfexpanding TAVI procedures/ to replace the aortic valve percutaneously and wwith a self-expanding NiTi cage; JenaValve was sold to Edwards in 2024 sucessfully. If you want to joyn our investment round possibly (and want to become a part of the word-wide leading cutting-edge technique for acute right heart patients) please get in touch with us (info@novapump.de). Today's mortality rate is for aRHF patients about 50% (30d) so we have the aim & the potential to become a market leader here!